1.Characteristics and Treatments of Large Cystic Brain Metastasis: Radiosurgery and Stereotactic Aspiration.
Moinay KIM ; Stephanie CHEOK ; Lawrance K CHUNG ; Nolan UNG ; Kimberly THILL ; Brittany VOTH ; Do Hoon KWON ; Jeong Hoon KIM ; Chang Jin KIM ; Stephen TENN ; Percy LEE ; Isaac YANG
Brain Tumor Research and Treatment 2015;3(1):1-7
Brain metastasis represents one of the most common causes of intracranial tumors in adults, and the incidence of brain metastasis continues to rise due to the increasing survival of cancer patients. Yet, the development of cystic brain metastasis remains a relatively rare occurrence. In this review, we describe the characteristics of cystic brain metastasis and evaluate the combined use of stereotactic aspiration and radiosurgery in treating large cystic brain metastasis. The results of several studies show that stereotactic radiosurgery produces comparable local tumor control and survival rates as other surgery protocols. When the size of the tumor interferes with radiosurgery, stereotactic aspiration of the metastasis should be considered to reduce the target volume as well as decreasing the chance of radiation induced necrosis and providing symptomatic relief from mass effect. The combined use of stereotactic aspiration and radiosurgery has strong implications in improving patient outcomes.
Adult
;
Brain*
;
Drainage
;
Humans
;
Incidence
;
Necrosis
;
Neoplasm Metastasis*
;
Radiosurgery*
;
Survival Rate
2.Systematic Analysis of Clinical Outcomes Following Stereotactic Radiosurgery for Central Neurocytoma.
Timothy T BUI ; Carlito LAGMAN ; Lawrance K CHUNG ; Stephen TENN ; Percy LEE ; Robert K CHIN ; Tania KAPREALIAN ; Isaac YANG
Brain Tumor Research and Treatment 2017;5(1):10-15
Central neurocytoma (CN) typically presents as an intraventricular mass causing obstructive hydrocephalus. The first line of treatment is surgical resection with adjuvant conventional radiotherapy. Stereotactic radiosurgery (SRS) was proposed as an alternative therapy for CN because of its lower risk profile. The objective of this systematic analysis is to assess the efficacy of SRS for CN. A systematic analysis for CN treated with SRS was conducted in PubMed. Baseline patient characteristics and outcomes data were extracted. Heterogeneity and publication bias were also assessed. Univariate and multivariate linear regressions were used to test for correlations to the primary outcome: local control (LC). The estimated cumulative rate of LC was 92.2% (95% confidence interval: 86.5-95.7%, p<0.001). Mean follow-up time was 62.4 months (range 3-149 months). Heterogeneity and publication bias were insignificant. The univariate linear regression models for both mean tumor volume and mean dose were significantly correlated with improved LC (p<0.001). Our data suggests that SRS may be an effective and safe therapy for CN. However, the rarity of CN still limits the efficacy of a quantitative analysis. Future multi-institutional, randomized trials of CN patients should be considered to further elucidate this therapy.
Brain Neoplasms
;
Follow-Up Studies
;
Humans
;
Hydrocephalus
;
Linear Models
;
Neurocytoma*
;
Particle Accelerators
;
Population Characteristics
;
Publication Bias
;
Radiosurgery*
;
Radiotherapy
;
Tumor Burden